Federal Register / Vol. 74, No. 183 / Wednesday, September 23, 2009 / Notices 48569 

funded entirely or partially by the 

Children’s Bureau through grants, 

contracts, and interagency agreements. 

The cross-site evaluation uses a 

mixed-method, longitudinal approach to 

examine the ICs (funded in FY 2009) 

and a new cohort of NRCs (funded in FY 

2010). Proposed data collection methods 

are a longitudinal telephone survey of 

State child welfare directors (or their 

designees) and Tribal Child Welfare/ 

Social Service Directors (or their 

designees), a web-based survey of State 

and Tribal T/TA recipients, and 

aggregation of outputs from a web-based 

technical assistance tracking system 

(OneNet)that will be used by the five ICs 

and 11 NRCs. A web-based survey will 

be also administered to members of the 

T/TA Network. Data collected through 

these instruments will be used by the 

Children’s Bureau to evaluate the 

effectiveness of technical assistance 

delivered to State, local, Tribal, and 

other publicly administered or publicly 

supported child welfare agencies and 

family and juvenile courts and the 

overall functioning of the T/TA 

Network. 

Respondents: Respondents to two of 

the survey instruments will be State and 

Tribal governments. Respondents to the 

third survey instrument will be private 

institutions, including universities, notfor-profit organizations, and private 

companies. Private institutions, 

including universities and not-for-profit 

organizations will be respondents to the 

forms in the OneNet tracking system. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average burden 

hours per 

response 

Total burden 

hours 

Agency Results Survey ............................................................................. 74 1 1 74 

Training and Technical Assistance (T/TA) Activity Survey ....................... 600 1 0 .25 150 

Web-Based Network Survey ..................................................................... 30 1 0 .25 7 .50 

OneNet Form: Implementation Project (IP) Description ............................ 5 5 .40 0 .50 13 .50 

OneNet Form: IP Technical Assistance (TA) Activity ................................ 5 280 .80 0 .33 463 .32 

OneNet Form: Implementation Center (IC) General TA Event ................. 5 4 0 .33 6 .60 

OneNet Form: IP Monthly Report .............................................................. 5 62 .40 0 .17 53 .04 

OneNet Form: National Resource Centers (NRC) TA Intake Form .......... 11 45 0 .13 64 .35 

OneNet Form: NRC TA Work Plan ........................................................... 11 45 0 .20 99 

OneNet Form: NRC TA Close-Out ............................................................ 11 45 0 .08 39 .60 

OneNet Form: NRC TA Activity ................................................................. 11 528 0 .20 1,161 .60 

OneNet Form: NRC General TA Event ..................................................... 11 36 0 .25 99 

Estimated Total Annual Burden 

Hours: 2,231.51. 

In compliance with the requirements 

of Section 506(c)(2)(A) of the Paperwork 

Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: September 18, 2009. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. E9–22897 Filed 9–22–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

A Plasmid System for Monitoring 

Double-Stranded DNA Breaks in the 

Live Cell 

Description of Technology: This 

technology is useful for studying the 

role of chromosomal breaks in cancer 

and for drug and assay development 

related to treating cancer. The 

technology is a two-plasmid system for 

inducing and monitoring individual 

double-stranded DNA breaks in the 

nuclei of live cells. The first plasmid, 

lac-I-SceI-tet, which is stably transfected 

into cells, has a rare 18 base pair 

restriction endonuclease site called 

ISceI. This site is flanked by an array of 

256 copies of the lac-repressor binding 

site and 96 copies of the tetracycline 

response element. Plasmids expressing 

tet and lac repressor proteins labeled in 

a complementary fashion can be 

cotransfected to visualize these arrays of 

repressor binding sites. The second 

mstockstill on DSKH9S0YB1PROD with NOTICES

48570 Federal Register / Vol. 74, No. 183 / Wednesday, September 23, 2009 / Notices 

plasmid, RFP-I-SceI-GR, is a chimera 

between the ISceI endonuclease and the 

ligand binding domain of the 

glucocorticoid receptor (GR) in frame 

with red fluorescent protein (RFP). This 

GR chimera will translocate from the 

cytoplasm to the nucleus upon addition 

of triamcinolone acetonide, leading to 

rapid induction of a double-stranded 

break between the lac and tet arrays. 

Applications: 

• Tool for drug studies relating to 

DNA stability and repair. 

• Tool to probe the role of nuclear 

and DNA binding proteins in stability 

and repair. 

Inventors: Thomas A. Misteli and Evi 

Soutoglou (NCI). 

Related Publication: E Soutoglou, JF 

Dorn, K Sengupta, M Jasin, A 

Nussenzweig, T Ried, G Danuser, T 

Misteli. Positional stability of single 

double-strand breaks in mammalian 

cells. Nat Cell Biol. 2007 Jun;9(6):675– 

682. 

Patent Status: HHS Reference No. E– 

264–2009/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: This technology is 

available as a research tool under a 

Biological Materials License. 

Licensing Contact: Steve Standley, 

PhD; 301–435–4074; sstand@od.nih.gov. 

Mouse Embryonic Stem Cell-Based 

Functional Assay To Evaluate 

Mutations in BRCA2 

Description of Technology: Mutations 

in breast cancer susceptibility genes 

BRCA1 and BRCA2 have up to an 80 

percent life time risk in developing 

breast cancer. There are no ‘‘mutation 

hot spots’’ and to date, more than 1,500 

different mutations have been identified 

in BRCA2. The absence of tumor cell 

lines expressing various mutant BRCA2 

alleles has hindered evaluations to 

determine the functional differences 

between different mutations. 

A simple, versatile and reliable mouse 

embryonic stem cell and bacterial 

artificial chromosome based assay to 

generate cell lines expressing mutant 

human BRCA2 has been developed and 

it has been used to classify 17 sequence 

variants. Available for licensing are 

wild-type and eleven mutant BRCA2 

cell lines developed from this assay that 

have either truncations or point 

mutations. These cell lines may be used 

to evaluate the effect of DNA damaging 

agents, genotoxins and 

chemotherapeutic efficacy. 

Applications: 

• Research tool to generate and study 

BRCA2 mutations. 

• Method to screen for 

chemotherapeutics. 

• Method to evaluate DNA damaging 

agents. 

Advantages: Ready to use portfolio of 

BRCA2 mutant cell lines to study 

BRCA2 mutant functional analysis. 

Market: An estimated 194,280 new 

cases of breast cancer will be diagnosed 

and may cause 40,610 deaths in the U.S. 

in 2009. 

Inventors: Shyam K. Sharan and 

Sergey Kuznetsov (NCI). 

Publication: SG Kuznetsov et al. 

Mouse embryonic stem cell-based 

functional assay to evaluate mutations 

in BRCA2. Nat Med. 2008 

Aug;14(8):875–881. 

Patent Status: HHS Reference No. E– 

261–2007/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Jennifer Wong; 

301–435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The Mouse Cancer Genetics Program, 

Center for Cancer Research, National 

Cancer Institute, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize mouse embryonic stem 

cell lines suitable for functional analysis 

of BRCA2 variants. Please contact John 

D. Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Establishment of Two Cell Lines That 

Stably Express Luciferase for In Vivo 

Tracking 

Description of Technology: Available 

for licensing are two renal carcinoma 

cell lines, 786-O(luc) and 786-O/VHL/ 

(luc) which both stably express 

luciferase. 786-O(luc) lacks von HippelLandau (VHL) protein expression and it 

has constitutively high expression of 

hypoxia-inducible transcription factor2alpha (HIF-2alpha). The second stably 

expresses VHL, a tumor suppressor, and 

has minimal HIF-2alpha expression. 

These cell lines can be tracked in vivo 

and can be used to study VHLdependent and HIF-2alpha dependent 

events such as tumorigenesis. VHL 

mutations lead to the clinical 

manifestations of von Hippel-Lindau 

disease, a rare autosomal dominant 

syndrome characterized by abnormal 

growth of blood vessels in multiple 

organs, including the brain and kidneys. 

Applications: Model to study VHL 

pathology. 

Advantages: Cell lines that stably 

express luciferase for in vivo tracking. 

Benefits: Easy, ready to use positive 

and negative VHL and HIF-2alpha cells 

that stably express luciferase for in vivo 

tests. 

Market: 

• Incidence of VHL syndrome is 1 in 

38,951. 

• HCC is the third leading cause of 

cancer death worldwide. 

• HCC is the fifth most common 

cancer in the world. 

• Post-operative five-year survival 

rate of HCC patients is 30–40 percent. 

Inventors: Leonard M. Neckers and W. 

Marston Linehan (NCI). 

Patent Status: HHS Reference No. E– 

005–2007/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Jennifer Wong; 

301–435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Urologic 

Oncology Branch, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

develop further uses for these two cell 

lines that stably express luciferase for in 

vivo tracking. Please contact John D. 

Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: September 17, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–22974 Filed 9–22–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

mstockstill on DSKH9S0YB1PROD with NOTICES